IntegraGen of France raises 6.3 mill euros

21 June 2001

IntegraGen, a French biotechnology firm that discovers genes involved incomplex diseases, has managed to raise 6.3 million euros ($5.4 million) in a private financing. The placement "attracted several international venture-capital companies," the firm said, including CDC Innovation 2000, based in Paris, and the Munich, Germany-headquartered Bay Tech.

IntegraGen, which was founded in July last year as a spin-off of Centre National Genotypage, said that its approach is centered on its GenomeHIP technology platform, "which overcomes the many limitations associated with existing methods," such as family linkage and single nucleotide polymorphism association studies. Chief executive Jean-Luc Gerbier said that this fundraising "will permit us to rapidly become a major player in the post-genomic market."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.